CN101095681A - Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same - Google Patents
Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same Download PDFInfo
- Publication number
- CN101095681A CN101095681A CNA2007100120681A CN200710012068A CN101095681A CN 101095681 A CN101095681 A CN 101095681A CN A2007100120681 A CNA2007100120681 A CN A2007100120681A CN 200710012068 A CN200710012068 A CN 200710012068A CN 101095681 A CN101095681 A CN 101095681A
- Authority
- CN
- China
- Prior art keywords
- alfuzosin hydrochloride
- permeating
- coating
- controlled release
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention belongs to medical technique field, and relates to osmotic pump controlled-release tablets of alfuzosin hydrochloride and the preparation method, which comprises tablet core, clothing sheet membrane and controlled-release pore. The solid medicine and osmotic active substance and shaping agent forms the tablet core; the coating membrane is insoluble controlled-release clothing sheet that is water permeable but not medical permeable. Said pore is on the clothing sheeting membrane. The comprised raw material of tablet core and clothing sheet membrane and proportion by weight are as follows: table core: alfuzosin hydrochloride 0.5-50%, packing agent 5-80%, penetration -promoting agent 5-80%, lubricating agent 0.2-3%, adhesive agent 0.01-10%; clothing sheet membrane: semi-permeable membrane clothing sheet high polymer material 70-99%, plasticizing agent 1-30%. The invention is characterized by stable and continuous release, long retention time for effective blood concentration and reduced peak-to-valley of blood concentration phenomena.
Description
Technical field:
The invention belongs to medical technical field, relate to the novel drugs dosage form of alfuzosin hydrochloride, exactly is alfuzosin Hydrochloride permeating pump type controlled-release preparation and preparation method thereof.
Background technology:
Alfuzosin hydrochloride (Alfuzosin), the another name Xatral is a kind of selectivity alpha 1-receptor blocker.Pharmacological research outside organism is verified, and alfuzosin hydrochloride has specificity for trigone of bladder portion, urethra and prostatic alpha 1-receptor, can reduce urethra pressure, thereby reduces voiding resistance, the treatment benign prostatic hyperplasia.A perspective study of 12 months by a definite date that has 5849 routine Benign Prostatic Hypertrophy to participate in shows, accepts alfuzosin hydrochloride every day 3 times, each 2.5mg person, and doing well,improving, quality of life improves.A short-term research shows, takes alfuzosin hydrochloride twice every day, each 5mg, and the maximum urine of patient flow increases, and the bladder residual urine volume reduces.The result of study of domestic Xu Wen space etc. also shows, takes the alfuzosin hydrochloride slow releasing tablet every day 2 times, each 5mg, and contrast other medicines therapeutic effect is better and cost is lower.Chinese patent 95104072.3 discloses the slow releasing preparation of alfuzosin hydrochloride, its formation be a kind of more than pH7 dissolved coated tablet, discharge at colon thereby reach active component.Chinese patent 200380105088.3 discloses the slow releasing composition that contains alfuzosin, mainly comprises alfuzosin or its pharmaceutically acceptable salt, solvate, enantiomer or their mixture and one or more resistances and is interpreted into branch.Chinese patent 200410042295.5 discloses the tablet of alfuzosine chlorhydrate controlled release, and it is double-layer tablet or three-layer tablet, its technology relative complex.The preparation of alfuzosin mainly contains the alfuzosin sheet in the market, and alfuzosin slow releasing tablet, prior dosage form can not be fit to needs clinically far away, and exploitation slow releasing preparation once-a-day meets the needs of medical market.
Osmotic pump preparation the earliest is nineteen fifty-five two Australian scholar's inventions, be used for the administration of domestic animal gastrointestinal, be called Rose-Nelson type osmotic pumps, the seventies, Theeuwes invented the basic theories of relevant osmotic pumps, establish the special status of osmotic pump preparation in controlled release preparation, and proposed the notion and the structure of elementary elementary osmotic pump, simplified the infiltration pump structure, thereby make it to move towards the industrialization production and clinical, the increasing also corresponding appearance of osmotic pumps product.The medicine of making osmotic pump preparation at present has albuterol, nifedipine, glipizide, diltiazem, doxazosin, indomethacin etc.Because osmotic pumps has: the strong dose thing can be provided; The character of scalable semipermeable membrane, thickness, surface area and release aperture etc. are to obtain required rate of releasing drug; Release and environment (as pH, stirring, feed situation etc.) are irrelevant, even irrelevant with the character of medicine, and the inside and outside dependency is good, so release situation in the available external release data prediction body; Can be used for regulating blood level; Can be by the multiple medicine of different rates while controlled release; Reduce medicining times, improve compliance; Reduce advantages such as stimulation and untoward reaction, people are used more it pay close attention to.
The alfuzosin hydrochloride good water solubility is not easy to control rate of releasing drug, and long-time steadily release of control medicine is its main difficulty, is that the difference between product is criticized and criticized is big on the other hand, is difficult for carrying out industrialized great production.
Summary of the invention:
The purpose of this invention is to provide alfuzosin Hydrochloride permeating pump type controlled-release preparation of a kind of constant release in vivo and preparation method thereof.The label that it is made by solid drugs and osmotic pressure active substance, excipient, outsourcing one deck can be permeable but can not be seen through the controlled release coat of the insoluble thin film of medicine, have aperture on this clothing film.
Purpose of the present invention can reach by following measure:
It is made up of following component:
The alfuzosin Hydrochloride permeating pump controlled release preparation, it is made up of label, coating membrane, drug release hole three parts, its label said preparation by weight percentage contains following composition: alfuzosin hydrochloride 0.5%～50%, penetrating agent 5%～80%, filler 5～80%, lubricant 0.2～3%, binding agent 0.01%～10%.
The coating membrane of alfuzosin Hydrochloride permeating pump controlled release preparation consists of: by weight calculating, macromolecular material is 70%～99%, can be one or more the combination of macromolecular material; Plasticizer is 1%～30% in the coating membrane, can be one or more plasticizer combinations.
Coating membrane is a macromolecular material, be polyolefin, polyester, cellulose esters or Eudragit, cellulose acetate, ethyl cellulose, polrvinyl chloride, Merlon, vinyl alcohol, vinylacetate and ethylene-propylene polymer, be mainly the cellulose acetate series of products and be: a cellulose acetate, cellulose diacetate, Triafol T etc.; Plasticizer is citric acid triacetic acid, triglyceride, phthalic acid ester, PEG400, polyethylene glycol 1500, Macrogol 4000, polyethylene glycol 6000, glyceride, succinate, benzoate, phosphate ester, adipate ester, tartrate etc. in the coating membrane; The coating solvent is mixed solvents such as acetone, acetone and isopropyl alcohol, acetone and chloroform.
The preparation method of alfuzosin Hydrochloride permeating pump controlled release preparation is as follows: with crossing 100 mesh sieves behind the medicine of recipe quantity and filler, the penetrating agent pulverize separately, behind the mix homogeneously, add binding agent system soft material, 18 mesh sieves are granulated, 45 ± 5 ℃ of dryings, 16 order granulate, dried granule add lubricant and suppress the heart in blocks.Label is placed in the coating pan, be blown into hot-air, when treating that the label temperature is 45 ℃ of left and right sides, carry out coating, the coating solution flow velocity is 5-10mL/min, and the coating kettle temperature is 45 ℃, and the coating pan rotating speed is 10-20rpm, till reaching predetermined standard time to the thickness of label outer coatings film, continue to be blown into hot-air 0.5h, with coated tablet 45 ℃ of following dry 12h in drying baker, get the coated tablet that above-mentioned drying finishes then, break into the aperture that the aperture is 0.4mm with mechanical means in coated tablet one side, get product.
In starch, pregelatinized Starch, dextrin, lactose, the microcrystalline Cellulose one or more of consisting of of the filler of the tablet described in the above-mentioned preparation method mix by arbitrary proportion.
Penetrating agent described in the above-mentioned preparation method is sodium chloride, potassium chloride, magnesium sulfate, magnesium chloride, potassium sulfate, sodium sulfate, d-mannitol, carbamide, glucose, sucrose, Magnesium succinate, tartaric acid etc.
The binding agent of the tablet described in the above-mentioned preparation method is the water of polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, methylcellulose, water, arbitrary proportion or the mixed solution of alcohol.
The lubricant of the tablet described in the above-mentioned preparation method is pharmaceutically useful adjuvant with lubrication, comprises magnesium stearate, Pulvis Talci, sodium lauryl sulphate.
The alfuzosin hydrochloride controlled release tablet of utilizing the present invention to prepare, the specification of alfuzosin hydrochloride are per unit 10mg, take once each 1 on the 1st.
24 hours slow releasing tablet Xatral of alfuzosin hydrochloride controlled release tablet and the production of Hangzhou Sai Nuofeishengdelabao pharmaceutical Co. Ltd are carried out release relatively, the results are shown in accompanying drawing 1.As seen from the figure, the more commercially available slow releasing tablet of rate of release (Xatral24) of self-control alfuzosin controlled release tablet (AH EOP) is more constant between 0～16 hour.According to similar factors, the release profiles of the two has very high similarity degree, and release in vitro difference as a result is little.
Theoretically, controlled release preparation is than ordinary preparation, and it is steady to have in the body blood drug level, the effective blood drug concentration length of holding time; Reduce blood drug level " peak valley " phenomenon, thereby alleviate the toxicity of medicine; Reduce administration number of times, characteristics such as make things convenient for administration and take.
From therapeutic compliance, ordinary tablet is taken medicine for three times on the one, and the patient often forgets easily take medicine daytime, and the interval of taking medicine daytime is shorter, and the back of taking medicine evening long the time in the morning to, causes morning time-out blood drug level low.Controlled release tablet was taken medicine once on the 1st, reduced medicining times, took medicine on time easily, keep 24 hours blood drug level steadily, so can overcome above-mentioned contradiction, be beneficial to patient treatment.
The alfuzosin Hydrochloride permeating pump controlled release preparation, once-a-day, blood drug level is steady in the body, and effective blood drug concentration is held time and is reached 24 hours, has reduced the peak valley phenomenon of blood drug level, has alleviated the toxicity of medicine.With commercially available Xatral 24h slow releasing tablet serves as that relative bioavailability and pharmacokinetic are carried out in contrast, and the result shows that the alfuzosin Hydrochloride permeating pump controlled release tablet is compared with control formulation, C
MaxReduce T
MaxAfter move, relative bioavailability is 105.1%, sees accompanying drawing 2.The inside and outside is the correlation research result show, the alfuzosin Hydrochloride permeating pump controlled release tablet has shown better inside and outside dependency (r=0.9362).
Advantage of the present invention is: the alfuzosin hydrochloride controlled release tablet of utilizing the present invention to prepare, and blood drug level is steady in the body of oral back, and side effect reduces, and administration number of times is few, and duration of efficacy is long.Alfuzosin release in gastrointestinal tract is slow, and the concentration that medicine contacts with gastrointestinal mucosa is little, has also alleviated the stimulation that gastrointestinal tract is caused.The present invention has overcome " peak valley " phenomenon of ordinary preparation blood drug level, the osmotic pump preparation technology is applied to alfuzosin hydrochloride, reach stable blood concentration, improve drug safety, reduce and take number of times, with side effect that reduces ordinary preparation and the compliance that improves the patient, more convenient patient uses, and can obtain the constant release of medicine in the different time scope.
Description of drawings:
Fig. 1 is the contrast of alfuzosin Hydrochloride permeating pump controlled release tablet and commercially available Xatral slow releasing tablet release in vitro degree
Fig. 2 is that 6 domesticated dogs give average blood drug level-time graph in alfuzosin Hydrochloride permeating pump controlled release tablet and the commercially available Xatral slow release lamellar body
The specific embodiment:
Prescription scope among the following embodiment can be selected in above-mentioned weight percentage ranges, and embodiment does not limit the range of choice.
Embodiment 1:
The label prescription:
Alfuzosin hydrochloride 10.0g
Lactose 40.0g
Microcrystalline Cellulose 40.0g
Magnesium stearate 0.25g
The label preparation: adjuvant and principal agent are crossed 100 mesh sieves mix, with 95% ethanol system soft material, 18 mesh sieves are granulated, and aeration-drying in the 40-45 ℃ of baking oven adds magnesium stearate, crosses 16 mesh sieve mixing granulate, tabletting.
Coating fluid prescription:
Cellulose acetate 100g
PEG400 4g
Dibutyl phthalate 4g
Acetone 5L
Art for coating: label is placed in the coating pan, be blown into hot-air, when treating that the label temperature is 45 ℃ of left and right sides, carry out coating, the coating solution flow velocity is 5-7mL/min, the coating kettle temperature is about 45 ℃, reaches weightening finish 4.0-4.5% to the thickness of label outer coatings film, continues to be blown into hot-air 0.5h, then with coated tablet 45 ℃ of following dry 12h in drying baker, get the coated tablet that above-mentioned drying finishes, break into the aperture that the aperture is 0.4mm in coated tablet one side, get product with mechanical means.
Embodiment 2:
The label prescription:
Alfuzosin hydrochloride 10.0g
Sucrose 35.0g
Lactose 45.0g
Magnesium stearate 0.25g
The label preparation is with embodiment 1;
Coating fluid prescription:
Cellulose acetate 100g
Polyethylene glycol 1500 5g
Dibutyl phthalate 5g
Acetone 5L
Art for coating is with embodiment 1.
Embodiment 3:
The label prescription:
Alfuzosin hydrochloride 10.0g
Sodium chloride 40.0g
Pregelatinized Starch 40.0g
Magnesium stearate 0.25g
Label preparation: with embodiment 1.
Coating fluid prescription:
Cellulose acetate 100g
PEG400 4.5g
Dibutyl phthalate 4g
Acetone 5L
Art for coating: with embodiment 1.
Embodiment 4:
The domesticated dog pharmacokinetic studies:
EXPERIMENTAL DESIGN:
Six of common domesticated dogs, body weight (15+3kg), fasting 12h before taking medicine, took medicine for twice 7 days at interval, single dose intersects 1 (10mg/ sheet of oral self-control alfuzosin Hydrochloride permeating pump controlled release tablet, lot number 20050801) and 1 of commercially available Xatral 24h slow releasing tablet (Hangzhou Sai Nuofeishengdelabao pharmaceutical Co. Ltd, lot number: 20030702, every contains alfuzosin 10mg).
Result of the test:
Adopt the non-compartment kinetic theory of statistical moment that 6 domesticated dog blood medicine data are handled, from film-making and commercially available pharmacokinetic parameters result of calculation such as table 1 and table 2.
Pharmacokinetic parameters in 6 domesticated dog bodies of table 1 alfuzosin Hydrochloride permeating pump controlled release tablet
| No. | T max(h) | C max(ng/ml) | k e(l/h) | t 1/2(h) | AUC 0～36(ng·h/ml) |
| A B C D E F Mean SD | 0.15 0.08 0.16 0.13 0.05 0.11 0.11 0.04 | 4.65 8.43 4.41 5.28 13.87 6.58 7.20 3.76 | 8.00 7.00 5.00 7.00 7.00 8.00 7.00 1.10 | 110.83 85.59 120.50 115.85 76.43 125.52 105.79 22.20 | 1614.63 1170.91 1243.88 1470.55 1010.96 2106.70 1436.27 427.96 |
Pharmacokinetic parameters in 6 domesticated dog bodies of the commercially available Xatral 24h of table 2 slow releasing tablet
| No. | T max(h) | C max(ng/ml) | k e(l/h) | t 1/2(h) | AUC 0～36(ng·h/ml) |
| A B C D E F Mean SD | 0.14 0.13 0.09 0.08 0.09 0.08 0.10 0.03 | 5.10 5.27 7.68 9.23 7.90 8.93 7.35 1.78 | 6.00 8.00 4.00 4.00 5.00 6.00 5.50 1.52 | 183.97 106.55 201.74 160.19 148.07 189.74 165.05 34.78 | 1556.09 1380.52 1722.24 958.24 945.95 1929.59 1415.44 402.23 |
With the lower area of blood concentration-time curve AUC among the non-modeling statistics result
0 → tData are asked and are calculated and the relative bioavailability of reference preparation with the self-control osmotic pump controlled release tablet of dosage, and the result is 105.1%.
Claims (9)
1, alfuzosin Hydrochloride permeating pump controlled release preparation, it is made up of label, coating membrane, drug release hole three parts, and it is characterized in that: label contains following composition by weight percentage: alfuzosin hydrochloride 0.5%～50%, penetrating agent 5%～80%, filler 5～80%, lubricant 0.2～3%, binding agent 0.01%～10%; Coating membrane has following composition by weight percentage: semipermeable membrane coating macromolecular material 70%～99%, plasticizer are 1%～30%, and the solvent of dissolving coating membrane is mixed solvents such as acetone, acetone and isopropyl alcohol, acetone and chloroform.
2, alfuzosin Hydrochloride permeating pump controlled release preparation according to claim 1 is characterized in that: filler is that in starch, pregelatinized Starch, dextrin, lactose, the microcrystalline Cellulose one or more mix by arbitrary proportion.
3, alfuzosin Hydrochloride permeating pump controlled release preparation according to claim 1 is characterized in that: binding agent is selected from the water of polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, methylcellulose, water, arbitrary proportion or the mixed solution of alcohol.
4, alfuzosin Hydrochloride permeating pump controlled release preparation according to claim 1 is characterized in that: penetrating agent is selected from sodium chloride, potassium chloride, magnesium sulfate, magnesium chloride, potassium sulfate, sodium sulfate, d-mannitol, carbamide, glucose, sucrose, Magnesium succinate, tartaric acid.
5, alfuzosin Hydrochloride permeating pump controlled release preparation according to claim 1, it is characterized in that: lubricant is selected from magnesium stearate, Pulvis Talci, sodium lauryl sulphate.
6, alfuzosin Hydrochloride permeating pump controlled release preparation according to claim 1 is characterized in that: semipermeable membrane coating macromolecular material is selected from one or more in polyolefin, polyester, cellulose esters or Eudragit, cellulose acetate, ethyl cellulose, polrvinyl chloride, Merlon, vinyl alcohol, vinylacetate and the ethylene-propylene polymer; Plasticizer is one or more in citric acid triacetic acid, triglyceride, phthalic acid ester, PEG400, polyethylene glycol 1500, Macrogol 4000, polyethylene glycol 6000, glyceride, succinate, benzoate, phosphate ester, adipate ester, the tartrate in the coating membrane; The coating solvent is mixed solvents such as acetone, acetone and isopropyl alcohol, acetone and chloroform.
7, alfuzosin Hydrochloride permeating pump controlled release preparation according to claim 6 is characterized in that: described semipermeable membrane coating macromolecular material is a cellulose acetate, cellulose diacetate, Triafol T class cellulose acetate series of products.
8, the preparation method of alfuzosin Hydrochloride permeating pump controlled release preparation, it is characterized in that: select alfuzosin hydrochloride, filler, penetrating agent, lubricant, binding agent and 95% ethanol are an amount of, with medicine and filler, cross 100 mesh sieves behind the penetrating agent pulverize separately, mix homogeneously, with 95% ethanol is wetting agent system soft material, 18 mesh sieves are granulated, wet grain drying, tabletting promptly got label after 16 order granulate, dried granule added the lubricant mixing, and label is placed in the coating pan, be blown into hot-air, when treating that the label temperature is 45 ℃ of left and right sides, carry out coating, the coating solution flow velocity is 5-10mL/min, the coating kettle temperature is 45 ℃, the coating pan rotating speed is 10-20rpm, reach predetermined standard time to the thickness of label outer coatings film till, continue to be blown into hot-air 0.5h, then with coated tablet 45 ℃ of following dry 12h in drying baker, get the coated tablet that above-mentioned drying finishes, break into the aperture that the aperture is 0.4mm in coated tablet one side, get product with mechanical means.
9, alfuzosin Hydrochloride permeating pump controlled release preparation according to claim 1 is characterized in that: the specification of alfuzosin hydrochloride is per unit 10mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100120681A CN101095681B (en) | 2007-07-13 | 2007-07-13 | Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100120681A CN101095681B (en) | 2007-07-13 | 2007-07-13 | Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101095681A true CN101095681A (en) | 2008-01-02 |
| CN101095681B CN101095681B (en) | 2011-04-20 |
Family
ID=39009902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100120681A Expired - Fee Related CN101095681B (en) | 2007-07-13 | 2007-07-13 | Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101095681B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028668B (en) * | 2009-09-29 | 2012-03-21 | 鲁南制药集团股份有限公司 | Simvastatin osmotic pump controlled-release tablet |
| CN101380313B (en) * | 2008-10-16 | 2012-11-07 | 沈阳药科大学 | Famotidine high density type gastric retention osmotic pump controlled release preparation and preparation method thereof |
| CN102871982A (en) * | 2012-10-16 | 2013-01-16 | 中国科学院上海药物研究所 | Medicine osmotic pump preparation |
| CN102896315A (en) * | 2012-09-15 | 2013-01-30 | 安徽省怀远县尚冠模具科技有限公司 | Method for manufacturing top board of die |
| CN101703488B (en) * | 2008-12-16 | 2013-02-20 | 北京科信必成医药科技发展有限公司 | Two-layer osmotic pump controlled release tablet with lubricating layer structure and preparation method thereof |
| CN111067114A (en) * | 2020-01-15 | 2020-04-28 | 翟国松 | Automatic apple coring device |
| CN114209668A (en) * | 2022-01-13 | 2022-03-22 | 山东新时代药业有限公司 | Alfuzosin hydrochloride sustained release preparation and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20050391A1 (en) * | 2005-03-11 | 2006-09-12 | Ph & T S P A | CONTROLLED RELEASE FORMULATIONS OF ALFUZOSIN |
-
2007
- 2007-07-13 CN CN2007100120681A patent/CN101095681B/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101380313B (en) * | 2008-10-16 | 2012-11-07 | 沈阳药科大学 | Famotidine high density type gastric retention osmotic pump controlled release preparation and preparation method thereof |
| CN101703488B (en) * | 2008-12-16 | 2013-02-20 | 北京科信必成医药科技发展有限公司 | Two-layer osmotic pump controlled release tablet with lubricating layer structure and preparation method thereof |
| CN102028668B (en) * | 2009-09-29 | 2012-03-21 | 鲁南制药集团股份有限公司 | Simvastatin osmotic pump controlled-release tablet |
| CN102896315A (en) * | 2012-09-15 | 2013-01-30 | 安徽省怀远县尚冠模具科技有限公司 | Method for manufacturing top board of die |
| CN102896315B (en) * | 2012-09-15 | 2015-04-01 | 安徽省怀远县尚冠模具科技有限公司 | Method for manufacturing top board of die |
| CN102871982A (en) * | 2012-10-16 | 2013-01-16 | 中国科学院上海药物研究所 | Medicine osmotic pump preparation |
| CN111067114A (en) * | 2020-01-15 | 2020-04-28 | 翟国松 | Automatic apple coring device |
| CN111067114B (en) * | 2020-01-15 | 2022-08-16 | 翟国松 | Automatic apple coring device |
| CN114209668A (en) * | 2022-01-13 | 2022-03-22 | 山东新时代药业有限公司 | Alfuzosin hydrochloride sustained release preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101095681B (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2489140T3 (en) | Oral dosage forms for modified release comprising tasocitinib | |
| ES2743699T3 (en) | Ketamine oral dosage form | |
| AU2011268445B9 (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| CN101095681B (en) | Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same | |
| US20040052844A1 (en) | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins | |
| KR20080007252A (en) | Therapeutic combination in case of benign prostate hyperplasia | |
| NO965539L (en) | Pharmaceutical tacrine preparations | |
| CN102727458B (en) | Coating composition, solid preparation coated therewith, and method for preparing solid preparation | |
| CA2879603A1 (en) | Oral dosage forms for modified release comprising ruxolitinib | |
| CN102048701B (en) | Pitavastatin calcium enteric sustained-release micropill preparation and preparation method thereof | |
| CN103550183B (en) | A kind of Trimetazidine Hydrochloride osmotic pump controlled release tablet and preparation method thereof | |
| US20120003307A1 (en) | Levetiracetam controlled release composition | |
| CN100376230C (en) | Timing slow-releasing micrpill and its preparation | |
| JP5756548B2 (en) | PPI multiple dosage form | |
| CN104414992A (en) | Glipizide osmotic pump controlled release tablet | |
| CN102349880B (en) | Isradipine controlled-release tablets and preparation method thereof | |
| CN114681420A (en) | Phloroglucinol controlled-release tablet and preparation method thereof | |
| CN101773482B (en) | Three-stage pulsed release controlled release tablet and preparation method thereof | |
| CN101766581B (en) | Diltiazem hydrochloride timing controlled release tablet in group-hole released way and preparation method thereof | |
| CN101269056A (en) | Metoprolol salt oral administration impulse pellet preparation | |
| CN101259112A (en) | Sarpogrelate hydrochloride single layer osmotic pump regulated-release preparations and preparation thereof | |
| CN101627975A (en) | Barnidipine slow release preparation and method for preparing same | |
| CN101756929A (en) | Pharmaceutical preparation containing isosorbide mononitrate | |
| CN103860514B (en) | A kind of ditropan XL osmotic pump controlled release tablet and preparation method thereof | |
| CN101269059B (en) | Isosorbide dinitrate oral administration impulse pellet preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG YAODA PREPARATION NOVEL TECHNOLOGY CO., L Effective date: 20120118 Owner name: KANGYA PHARMACEUTICAL INDUSTRY CO., LTD., NINGXIA Free format text: FORMER OWNER: SHENYANG YAODA PREPARATION NOVEL TECHNOLOGY CO., LTD. Effective date: 20120118 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110016 SHENYANG, LIAONING PROVINCE TO: 750002 YINCHUAN, NINGXIA HUI AUTONOMOUS REGION |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120118 Address after: 750002 No. 6 road, hi tech Industrial Development Zone, Ningxia, Yinchuan Co-patentee after: Shenyang Pharmaceutical University Patentee after: Kangya Pharmaceutical Industry Co., Ltd., Ningxia Address before: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No. Patentee before: Shenyang Pharmaceutical University |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110420 Termination date: 20190713 |